๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease Who Are Still Symptomatic After Optimal Medical Treatment
NCT07041359Coronary Arterial Disease (CAD)
China National Center for Cardiovascular Diseases
Phase 4
120
Beijing
2025-08-18
Recruiting
To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL
NCT07143929CD7 Positive R/R PTCL
Peking University People's Hospital
Phase 1
18
Beijing
2025-08-18
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
NCT07086976Autoimmune Haemolytic Anaemia
Sanofi
Phase 3
90
Beijing, Chengde, Guangzhou, Hohhot, Nanchang, Suzhou, Tianjin, Wuhan
2025-08-18
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
NCT07280494CD7+ T-ALL/LBL
Peking University People's Hospital
Phase 1
18
Beijing
2025-08-18
Active, closed
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
NCT07081022B-cell Non-Hodgkin's Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
180
Beijing
2025-08-17
Not yet open
Chinese Ostomy Collaboration Group (COCG) Clinical Study -SITI Classification
NCT07111429Complication,Postoperative, Stoma
Peking University Cancer Hospital & Institute
Observational
5,000
Beijing
2025-08-15
Recruiting
Multi-omics Studies of Primary Aldosteronism
NCT07111351Primary Aldosteronism
Peking University First Hospital
Observational
400
Beijing
2025-08-15
Recruiting
Research on Identifying Critical Surgical Anatomy in Cholecystectomy Videos Based on Deep Learning
NCT07158372Cholecystectomy, Surgical Video Identification
Chinese Academy of Sciences
Observational
200
Zhengzhou, Beijing, Shanghai
2025-08-15
Recruiting
Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke
NCT07026318Acute Ischemic Stroke
Beijing Anzhen Hospital
Not applicable
716
Beijing
2025-08-15
Recruiting
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NCT07095023Breast Cancers
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
112
Beijing, Guangzhou, Shantou, Nanning, Guiyang, Haikou, Wenzhou, Shenzhen
2025-08-15
Recruiting
Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation
NCT07158710Malignant Brain Tumors
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
159
Beijing, Fuzhou, Guangzhou, Changchun, Shanghai
2025-08-15
Recruiting
Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease
NCT07181525Inflamatory Bowel Disease
Peking University First Hospital
Observational
200
Beijing
2025-08-15
By invitation
Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related Tumors
NCT07822347Tumor
Peking Union Medical College Hospital
Phase 1/2
20
Beijing
2025-08-15
Recruiting
Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study
NCT07284264Dementia
Xuanwu Hospital, Beijing
Observational
6,000
Beijing, Hainan, Ningxiang, Shenyang, Shenzhen, Yichun
2025-08-15
Recruiting
Clinical Application of Wearable Ultrasound Sensors
NCT07009873DVT - Deep Vein Thrombosis, POCUS
Chinese PLA General Hospital
Observational
300
Beijing
2025-08-15
Recruiting
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
NCT07023315Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Akeso
Phase 3
760
Beijing, Fuzhou, Shijiazhuang, Harbin, Shanghai, Tianjin
2025-08-14
Active, closed
A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer
NCT07777211Advanced Pancreatic Cancer, Ductal Adenocarcinoma of Pancreas
Beijing Gene Key Life Technology Co., Ltd
Phase 1/2
52
Beijing
2025-08-14
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
150
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-08-14
Not yet open
Prognostic Model for MASLD Related Cirrhosis
NCT07082751Metabolic Dysfunction Associated Steatotic Liver Disease, Compensated Cirrhosis
Beijing Friendship Hospital
Observational
228
Beijing, Tianjin
2025-08-13
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
NCT06994650Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
140
Beijing
2025-08-13
Recruiting
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function
NCT07144098Obesity/Overweight
Gan & Lee Pharmaceuticals.
Phase 1
24
Beijing
2025-08-12
Recruiting
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
NCT07193459Type 2 Diabetes
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
360
Beijing
2025-08-12
Active, closed
Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)
NCT07246889Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 3
577
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-12
Active, closed
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07021976Obstructive Hypertrophic Cardiomyopathy
Shandong Suncadia Medicine Co., Ltd.
Phase 3
228
Beijing
2025-08-11
Recruiting
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT07460362MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Peking University Third Hospital
Phase 2
43
Beijing
2025-08-11
Recruiting
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
NCT07105215Solid Tumors
RemeGen Co., Ltd.
Phase 1/2
312
Beijing, Fuzhou, Xiamen, Guilin, Nanning, Harbin, Luoyan, Luoyang
2025-08-11
Recruiting
Shame-Focused Cognitive Behavioral Therapy For Reducing Suicide Risk In Adolescent Psychiatric Inpatients (SF-CBT)
NCT07294001Adolescent Suicide, Suicidal Ideation, Suicidal Behavior, Shame
Peking University
Not applicable
42
Beijing
2025-08-10
Not yet open
ERP-Based Research on the Modulation of Remimazolam on Working Memory and Brain Network Mechanisms in Glioma Patients
NCT07109362Remimazolam Mild Sedation, Healthy Brain and Glioma Brain
Beijing Tiantan Hospital
Not applicable
60
Beijing
2025-08-10
Recruiting
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
NCT07239947Atopic Dermatitis
Bambusa Therapeutics
Phase 1
99
Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang
2025-08-09
Recruiting
Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
NCT07152639Tuberculosis
Chengdu CoenBiotech Co., Ltd
Phase 3
1,784
Beijing, Hunan, Liuzhou, Xinxiang, Wuhan, Yichang, Chengdu
2025-08-09
Recruiting
Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease
NCT07031531Premature Coronary Heart Disease
China National Center for Cardiovascular Diseases
Not applicable
4,900
Hefei, Beijing, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Nanjing, Yangzhou
2025-08-08
By invitation
A Randomized Trial of Six-Channel RF Ablation System for Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease
NCT07130955Hypertension, CKD - Chronic Kidney Disease
Shanghai Golden Leaf MedTec Co. Ltd
Not applicable
236
Beijing
2025-08-08
Active, closed
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus
NCT07055386Type 2 Diabetes Mellitus (T2DM)
Gan & Lee Pharmaceuticals.
Phase 2
90
Beijing
2025-08-07
Active, closed
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
NCT07162181Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
Eli Lilly and Company
Phase 2
13
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan
2025-08-07
By invitation
"Real-world Assessment of BP Control in Patients With Hypertension by the Netrod RDN System" - REACH-RDN
NCT07273877Hypertension
Shanghai Golden Leaf MedTec Co. Ltd
Observational
1,000
Beijing
2025-08-07
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
AstraZeneca
Phase 3
250
Beijing, Changsha, Chengdu, Chongqing, Nanjing, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Beijing, Tianjin
2025-08-06
Recruiting
Interventional Left Ventricular Assist System for PCI in CHIP Patients
NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
286
Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang
2025-08-06
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Recruiting
A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
NCT07103668Gastric Adenocarcinoma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase 3
150
Beijing
2025-08-06
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
AstraZeneca
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua
2025-08-06
Recruiting
The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease
NCT07080775Parkinson's Disease
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Phase 1
12
Beijing
2025-08-05
Recruiting
To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice
NCT07029451Infertility
Ferring Pharmaceuticals
Observational
2,500
Hefei, Maโ€™anshan, Beijing, Chaoyang, Xicheng, Guangzhou, Shantou, Nanning
2025-08-05
Active, closed
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT07081633Hepatocellular Carcinoma
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
NCT07038382Membranous Nephropathy, Lupus Nephritis (LN)
Shanghai Henlius Biotech
Phase 2
24
Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing
2025-08-05
Recruiting
Study on the Improvement of Metabolic Indicators in Type 1 Diabetes Patients
NCT07144696Type 1 Diabetes Mellitus
Peking University First Hospital
Not applicable
150
Beijing
2025-08-05
Recruiting
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
NCT07042126Dermatitis, Atopic
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
180
Beijing, Jinhua, Nanchang
2025-08-05
Recruiting
Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation
NCT06871228Atrial Fibrillation (AF)
Beijing Anzhen Hospital
Not applicable
4,100
Hefei, Beijing, Guangzhou, Shijiazhuang, Harbin, Luohe, Zhengzhou, Wuhan
2025-08-05
Recruiting
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
NCT06615596Atrial Fibrillation (AF)
China National Center for Cardiovascular Diseases
Phase EARLY_PHASE1
3,160
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Shanghai, Taiyuan, Chengdu
2025-08-05
Recruiting
Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation
NCT06952842Retinitis Pigmentosa
Chigenovo Co., Ltd
Phase 1/2
18
Beijing
2025-08-04
Recruiting
Novel Biomarkers and Postoperative Kidney Injury in Radical Nephrectomy
NCT07088874Nephrectomy, Acute Kidney Injury, Biomarker
Peking University First Hospital
Observational
60
Beijing
2025-08-02
Recruiting
Real World Evidence Study of SYN023 in Children Exposed to Rabies
NCT07327307Rabies Post-exposure Prophylaxis
Synermore Biologics (Suzhou) Co., Ltd.
Observational
232
Beijing, Shenzhen, Changsha, Hengyang, Nanchang
2025-08-02
Recruiting
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
NCT06970912Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
Peking University People's Hospital
Phase 2
393
Beijing
2025-08-01
Recruiting
68Ga-NYM096 PET/CT in Various Kinds of Cancer
NCT07144748Cancer
Peking Union Medical College Hospital
Not applicable
120
Beijing
2025-08-01
Recruiting
Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis
NCT07045155Dialysis; Complications, Chronic Kidney Disease 5D, Renal Anemia of Chronic Kidney Disease, Renal Anaemia
Chinese PLA General Hospital
Phase 4
240
Beijing
2025-08-01
Not yet open
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1
NCT07032116Diabetic Kidney Disease (DKD)
Liu Hongfang
Observational
4,472
Beijing, Guangzhou, Changchun, Tianjin
2025-08-01
Recruiting
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
NCT07257510Mantle Cell Lymphoma (MCL), POZ
Peking University Third Hospital
Not applicable
34
Beijing
2025-08-01
Not yet open
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
NCT07083375Extensive Small Cell Lung Cancer
Zhijie Wang
Phase 2
56
Beijing
2025-08-01
Recruiting
Basic and Clinical Study of Cardiac Ganglion Catheter Ablation for the Treatment of Significant Bradycardia
NCT07468383Symptomatic Bradycardia, Autonomic Nervous System Diseases
Beijing Anzhen Hospital
Not applicable
188
Beijing
2025-08-01
Not yet open
Precise Phenotyping Classification in Atrial Fibrillation
NCT07044011Atrial Fibrillation
China National Center for Cardiovascular Diseases
Observational
1,000
Beijing
2025-08-01
Recruiting
Environmental Pollutants and Neurological Disorders
NCT07140601Cerebrovascular Disorders, Brain Tumours, Alzheimer Dementia
Beijing Tiantan Hospital
Observational
500
Beijing
2025-08-01
Recruiting
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
NCT06994507Chemotherapy-induced Peripheral Neuropathy (CIPN)
Qilu Pharmaceutical Co., Ltd.
Phase 3
352
Beijing
2025-08-01
Not yet open
A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
NCT07099794Biliary Tract Cancer (BTC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
90
Beijing
2025-08-01
Recruiting
Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease
NCT07323927Alzheimer Disease
Xuanwu Hospital, Beijing
Phase EARLY_PHASE1
10
Beijing
2025-08-01
Not yet open
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2
NCT07034807Diabetic Kidney Disease (DKD)
Liu Hongfang
Not applicable
228
Beijing, Guangzhou, Changchun, Tianjin
2025-08-01
Active, closed
JiGenerations Health Cohort Study๏ผšParental Exposure and Intergenerational Health in China
NCT07514377Environmental Exposure, Fertility, Health Problems in Pregnancy, Adverse Pregnancy Outcomes
National Research Institute for Family Planning, China
Observational
100,000
Beijing
2025-08-01
Recruiting
CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism
NCT04211181Venous Thromboembolic Disease, Pulmonary Embolism, Venous Thromboembolism, Deep Venous Thrombosis
China-Japan Friendship Hospital
Not applicable
5,800
Beijing
2025-08-01
By invitation
Digital Phenotyping of High-Risk Chronic Ventilator-Dependent Patients
NCT07656155Ventilator Dependency
China-Japan Friendship Hospital
Observational
30,500
Beijing
2025-08-01
Recruiting
Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD
NCT07523880Thrombosis, Bleeding, Coronary Artery Disease (CAD)
Xueyan Zhao
Observational
12,154
Zhengzhou, Shenyang, Beijing
2025-08-01
Recruiting
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
NCT06173219Advanced Solid Tumor
China-Japan Friendship Hospital
Phase 1/2
38
Beijing
2025-08-01
Not yet open
Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions
NCT07023575Interstitial Lung Abnormalities
China-Japan Friendship Hospital
Observational
100,000
Beijing, Shanghai, Changsha, Guiyang, Hangzhou, Henan, Qingdao, Shenyang
2025-08-01
Recruiting
Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease
NCT06674460Cerebral Small Vessel Disease, Ischemic Stroke
Peking Union Medical College Hospital
Phase 3
600
Beijing
2025-08-01
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
AstraZeneca
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-08-01
Active, closed
Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH
NCT07204041Langerhans Cell Histiocytosis (LCH)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2025-08-01
Not yet open
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms
NCT07077330Relapsed or Refractory Plasma Cell Neoplasms
Chinese PLA General Hospital
Phase EARLY_PHASE1
20
Beijing
2025-08-01
Not yet open
GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.
NCT07090538Neuroblastoma
Chinese PLA General Hospital
Phase EARLY_PHASE1
10
Beijing
2025-08-01
Not yet open
A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis
NCT07102888Plaque Psoriasis in Children, Plaque Psoriasis in Adolescents
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
20
Beijing
2025-08
Not yet open
pCAD-POAF 3 Year Follow-up
NCT07146061Coronary Artery Disease, Atrial Fibrillation
China National Center for Cardiovascular Diseases
Observational
430
Beijing
2025-08
Not yet open
KANGFUPEN Liquid Dressing for Chronic Radiation-Induced Rectal Injury
NCT07065175Chronic Radiation-induced Proctitis
Peking Union Medical College Hospital
Phase 2
65
Beijing
2025-08
Not yet open
Improvement of Skeletal and Muscle Health in Patients With Sarcopenia by Protein Powder With Resistance Exercise
NCT07049731Sarcopenia
Weiwei Ma
Not applicable
224
Beijing
2025-08
Not yet open
A Study of Collagen Scaffold for the Repair of Elbow Cartilage Injury
NCT07149896Cartilage Defect, Elbow Injury
Beijing Jishuitan Hospital
Phase 3
90
Beijing
2025-08
Not yet open
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
NCT07083739Primary Immune Thrombocytopenia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
320
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-08
Not yet open
Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients
NCT07079579Renal Anemia in Non-dialysis Chronic Kidney Disease
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 4
120
Beijing
2025-08
Not yet open
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
NCT07146386Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 3
728
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Shantou
2025-08
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.
NCT07058662DMD
Belief BioMed (Beijing) Co., Ltd
Phase 1/2
9
Beijing
2025-07-31
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
Pfizer
Phase 3
208
Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou
2025-07-31
Not yet open
Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor
NCT06998173Advanced Solid Tumors
Danatlas Pharmaceuticals Co., Ltd
Phase 1
228
Beijing
2025-07-31
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors
Amgen
Phase 1
434
Beijing, Chongqing, Jinan
2025-07-31
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
Recruiting
Marshall Vein Ethanol Infusion in Addition to Pulsed Electric Field Ablation Versus Pulsed Electric Field Ablation Alone for Paroxysmal Atrial Fibrillation
NCT07095959Atrial Fibrillation (AF)
Beijing Anzhen Hospital
Not applicable
340
Beijing
2025-07-31
Recruiting
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
NCT07007143Mitral Regurgitation
Chinese Academy of Medical Sciences, Fuwai Hospital
Phase 4
1,032
Beijing
2025-07-31
Recruiting
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
NCT07124936Diffuse Large B Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
97
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2025-07-30
Active, closed
A Food Effect Study of LY03020 in Healthy Subjects
NCT07292233Schizophrenia, Alzheimer's Disease Psychosis
Luye Pharma Group Ltd.
Phase 1
16
Beijing
2025-07-30
Recruiting
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
NCT06897046Non-small Cell Lung Cancer (NSCLC), II-IIIB
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
90
Beijing
2025-07-30
Recruiting
Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke
NCT07047014Stroke, Ischemic, Medium Vessel Occlusions
Beijing Tiantan Hospital
Phase 3
596
Beijing, Jiuquan, Shijiazhuang, Jiyuan, Lingbao, Nantong, Hangzhou
2025-07-30
Recruiting
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT06780111Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
298
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang
2025-07-30
Not yet open
A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment
NCT06772233Metastatic Gastrointestinal Stromal Tumors (GIST)
Peking University
Phase 2
100
Beijing
2025-07-30
Recruiting
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
NCT07079475Non-Small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 1/2
220
Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Shengyang, Jinan
2025-07-30
Recruiting
The Safety and Efficacy of Fecal Microbiota Transplantation Combined With Nutritional Intervention in the Treatment of Functional Constipation๏ผša Pilot Study
NCT07387952Constipation - Functional, Fecal Microbiota Transplantation (FMT), Chronic Constipation
Peking Union Medical College Hospital
Not applicable
5
Beijing
2025-07-30
Rows per page Showing 1801–1900 of 5484
Previous 17 18 19 20 21 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=19

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.